International Journal of General Medicine (Feb 2023)

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients

  • Priambada D,
  • Thohar Arifin M,
  • Saputro A,
  • Muzakka A,
  • Karlowee V,
  • Sadhana U,
  • Bakhtiar Y,
  • Prihastomo KT,
  • Risdianto A,
  • Brotoarianto HK,
  • Andar E,
  • Muttaqin Z

Journal volume & issue
Vol. Volume 16
pp. 393 – 403

Abstract

Read online

Dody Priambada,1 Muhamad Thohar Arifin,1 Abdi Saputro,1 Azka Muzakka,1 Vega Karlowee,2 Udadi Sadhana,2 Yuriz Bakhtiar,1 Krisna Tsaniadi Prihastomo,1 Ajid Risdianto,1 Happy Kurnia Brotoarianto,1 Erie Andar,1 Zainal Muttaqin1 1Department of Neurosurgery, Faculty of Medicine, Diponegoro University/Dr. Kariadi Hospital, Semarang, Indonesia; 2Department of Clinical Pathology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, IndonesiaCorrespondence: Muhamad Thohar Arifin, Department of Neurosurgery, Faculty of Medicine, Diponegoro University/Dr. Kariadi Hospital, Dr. Soetomo Street Number 16-18, Semarang, Indonesia, Tel +62 813 2586 1628, Email [email protected]: The current World Health Organization (WHO) 2021 classification of human glioma is based on key molecular biomarkers to define neoplastic entities. This review further delineates mutant IDH (isocitrate dehydrogenase) from wild-type IDH disease, a necessity given the large survival gap between mutant IDH and wild-type IDH tumors. In Indonesia, there are currently few reports on the distribution and significance of these mutations. Therefore, this research aims to determine the relationship between IDH mutations, as well as clinicopathological and prognostic factors in patients with gliomas. Other immunohistochemical markers including ATRX (alpha-thalassemia/mental retardation, X-linked), Ki67 and GFAP (glial fibrillary acidic protein) expression were also evaluated.Methods: Forty-two glioma samples were collected from patients who underwent surgery at Dr. Kariadi General Hospital in Semarang, Central Java, Indonesia. Fresh and paraffin-embedded, formalin-fixed tissue samples were removed and sectioned for hematoxylin and eosin staining, immunohistochemistry, and IDH analysis of mutation. Medical records were used to collect clinicopathological and survival data.Results: IDH1 mutations were discovered in 32 (76,1%) patients, and those with IDH1 mutation had longer overall survival when corresponded to patients with IDH1-wild-type. Lower expression of Ki67 was discovered to be very associated with a better prognosis.Conclusion: IDH1 mutations status showed a significant relationship with prognosis in patients with glioma. Meanwhile, other markers (ATRX, Ki67, and GFAP) did not correlate with the prognosis.Keywords: IDH1, immunohistochemical expression, prognosis, glioma, Indonesia

Keywords